Owkin: Alban de La Sablière appointed Chief Business Officer MyPharma Editions

Published Tuesday, October 4, 2022

Owkin, a biotech specializing in artificial intelligence applied to medical research, today announced the appointment of Alban de La Sablière as Chief Business Officer. Formerly Head of International Partnerships at Sanofi, his aim will be to support the company in its development and growth. Among his missions, he will ensure the commercial development of Owkin with its partners in the pharmaceutical industry, while structuring the development strategies of its platforms and solutions.

At the same time, Alban de La Sablière will monitor revenue growth, guarantee the intellectual property rights of initiated projects and promote strategic partnerships and opportunities for mergers and acquisitions as well as the granting of licenses for molecules and their disposal.

From the pharmaceutical industry to artificial intelligence applied to medical research

After graduating with an MBA from HEC in 1996, Alban de La Sablière began his career at Morgan Stanley. After 19 years at the bank, he left the structure as managing director responsible for mergers and acquisitions for the French market. In particular, he oversaw the transactions of Sanofi-Aventis, Suez-GDF and Unibail-Rodamco.

In 2016, he joined Sanofi, finishing there as SVP Global Head of Partnering. Within the company, Alban repositioned Sanofi’s business development efforts towards innovative medicines and signed significant partnership agreements with Denali, Kiadis, Kymera, Biond, Mab Discovery, Nurix, IGM, Seagen, Innovent and Translate Bio.

During this experience, Alban de La Sablière also restructured Sanofi’s strategy in terms of partnerships, business development, licensing and mergers and acquisitions under the direction of Paul Hudson, CEO of the company. He also showcased Sanofi’s ambitious digital health efforts through major partnerships with Owkin, Exscientia and Atomwise.

He was also responsible for Sanofi Ventures and significantly increased the fund’s activity by structuring several venture capital investments in the US and Europe. He has led more than $30 billion in acquisitions of companies at various stages of development, including Principia, Synthorx, Translate Bio, Kadmon, Bioverativ, Ablynx and Protein Sciences, as well as numerous divestitures, including the sale of Zentiva.

By joining Owkin, he will work closely with Thomas Clozel, CEO and co-founder of the French-American unicorn, to play a critical role in achieving the company’s mission of finding the right treatment for every patient.

“Owkin’s approach to medical research is revolutionizing the way we develop new treatments. Having spent years leading business development and partnership development at the top of the biopharma industry, I am extremely excited to join the most innovative biotech in the world. In our journey towards the emergence of a whole new generation of treatments for patients, we will help make Owkin the industry leader in the discovery and development of AI medicines.” rejoices Alban de La Sablière.

“I look forward to working hand in hand with Alban to revolutionize the way we treat and diagnose patients. His experience in our industry is second to none and he will play a key role in developing innovative treatments for patients. His sense of urgency and his dynamism match our pace of development and match our ambitions perfectly. comments Thomas Clozel.

Source and visual: Owkin

Leave a Comment